Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)

被引:88
作者
Hollen, PJ
Gralla, RJ
Kris, MG
Eberly, SW
Cox, C
机构
[1] Northeastern Univ, Sch Nursing, Boston, MA 02115 USA
[2] Ochsner Canc Inst, New Orleans, LA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Rochester, Dept Biostat, Rochester, NY USA
关键词
cancer; lung; quality of life trends; norms; Lung Cancer Symptom Scale;
D O I
10.1007/s005200050244
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Normative data and trends for a disease- and site-specific quality of life (QL) instrument for individuals with lung cancel; the Lung Cancer Symptom Scale (LCSS), are presented to facilitate the user's interpretation of test scores. Data for patients enrolled in two large, identical, randomized trials of a new combination chemotherapy regimen for patients with stages III and IV non-small-cell lung cancer (NSCLC) were combined into one dataset (n=673). For these patients with a Karnofsky performance status (KPS) of 60-100%, QL had been prospectively measured at baseline, day 29 and every 6 weeks thereafter. Descriptive statistics for the LCSS are presented for three time points (baseline, day 29 and day 71) and for specific demographic and disease-related characteristics (age, gender, race, performance status and stage of disease) to provide expected values and their variability during chemotherapy. Data from a small dataset of 63 NSCLC inpatients with KPS scores of 20-50% are also presented for a comparison sample of supportive care for inpatients and hospice patients. For the 673 NSCLC patients at baseline there were no significant differences in QL by age, gen-der, or race. Major presenting lung cancer symptoms at baseline for this combined sample were dyspnea 87%, cough 86% pain 81%, loss of appetite 75%, and hemoptysis 41%. Of these patients, 81% had three or more presenting symptoms at baseline (2% had no symptoms; 5%, one symptom; 12% two symptoms; 18%, three symptoms; 27%, four symptoms; and 36%, five symptoms). The mean LCSS baseline score (best = 0; worst = 100) was 26.56 (SD 16.10). The mean scores for day 29 and day 71 were 25.46 (SD 16.52) and 25.30 (SD 16.93), respectively, but follow-up assessments on progressers were not obtained. Stage III patients had a mean LCSS score of 23.7 (SD 15.1), whereas stage IV patients reported a mean LCSS score of 27.3 (SD 16.3). The mean LCSS score for the group with KPS 60-70% was 34.8 (SD 15.5), and that for the group with KPS 80-100% was 23.3 (SD 15.1). The mean LCSS score for the lower performance group, with KPS scores of 20-50% at baseline, was 46.85 (SD 17.65).
引用
收藏
页码:140 / 148
页数:9
相关论文
共 24 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]  
[Anonymous], 1996, J CLIN ONCOL, V14, P671
[3]  
[Anonymous], 2013, Clinical trials: a practical approach
[4]  
[Anonymous], 1995, ASSESSING QUALITY LI
[5]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[6]   RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY - LUNG (FACT-L) QUALITY-OF-LIFE INSTRUMENT [J].
CELLA, DF ;
BONOMI, AE ;
LLOYD, SR ;
TULSKY, DS ;
KAPLAN, E ;
BONOMI, P .
LUNG CANCER, 1995, 12 (03) :199-220
[7]  
COMIS R, 1994, LUNG CANCER S1, V11, P119
[8]  
Fayers P M, 1983, Stat Med, V2, P429
[9]  
FLETCHER AE, 1988, CANC CLIN TRIALS CRI, V111, P216
[10]  
GRALLA RJ, 1994, P AN M AM SOC CLIN, V13, P347